{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:23:42Z","timestamp":1773008622992,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vph.2019.106599","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T12:05:12Z","timestamp":1571313912000},"page":"106599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats"],"prefix":"10.1016","volume":"122-123","author":[{"given":"Zi Ping","family":"Leong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Hikasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2019.106599_bb0005","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1165\/rcmb.2010-0371OC","article-title":"Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats","volume":"45","author":"Abe","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.vph.2019.106599_bb0010","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdu237","article-title":"Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial","volume":"25","author":"Adenis","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.vph.2019.106599_bb0015","first-page":"329","article-title":"Oral tadalafil in pulmonary artery hypertension: a prospective study","volume":"59","author":"Aggarwal","year":"2007","journal-title":"Indian Heart J."},{"key":"10.1016\/j.vph.2019.106599_bb0020","first-page":"255","article-title":"Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs","volume":"54","author":"Arita","year":"2013","journal-title":"Can. Vet. J."},{"key":"10.1016\/j.vph.2019.106599_bb0025","doi-asserted-by":"crossref","first-page":"L333","DOI":"10.1152\/ajplung.00038.2015","article-title":"The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension","volume":"309","author":"Church","year":"2015","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.vph.2019.106599_bb0030","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"30","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2019.106599_bb0035","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.pharmthera.2012.12.003","article-title":"Role of Rho-kinase and its inhibitors in pulmonary hypertension","volume":"137","author":"Duong-Quy","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.vph.2019.106599_bb0040","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1097\/01.hjh.0000378810.75926.32","article-title":"Effects of tadalafil to prevent thickening of pulmonary artery in monocrotaline-induced pulmonary hypertension rats: compared with echocardiographic findings: pp.13.485","volume":"28","author":"Egawa","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.vph.2019.106599_bb0045","first-page":"273","article-title":"The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension","volume":"6","author":"Falk","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.vph.2019.106599_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089810","article-title":"CXCR4 inhibition ameliorates severe obliterative pulmonary hypertension and accumulation of C-kit+ cells in rats","volume":"9","author":"Farkas","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2019.106599_bb0055","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/jcmm.13026","article-title":"Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells","volume":"21","author":"Favre","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.vph.2019.106599_bb0060","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.healun.2015.05.025","article-title":"Long-term safety and efficacy of imatinib in pulmonary arterial hypertension","volume":"34","author":"Frost","year":"2015","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.vph.2019.106599_bb0065","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2019.106599_bb0070","first-page":"1488","article-title":"Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study","volume":"44","author":"Ghofrani","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2019.106599_bb0075","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1536\/ihj.51.272","article-title":"Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension","volume":"51","author":"Hatano","year":"2010","journal-title":"Int. Heart J."},{"key":"10.1016\/j.vph.2019.106599_bb0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/toxsci\/kfs192","article-title":"Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase","volume":"129","author":"Hu","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.vph.2019.106599_bb0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2019.106599_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104890","article-title":"Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines\/chemokines, MAP kinases and Akt","volume":"9","author":"Kiss","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2019.106599_bb0095","doi-asserted-by":"crossref","first-page":"P1342","DOI":"10.1093\/eurheartj\/ehx502.P1342","article-title":"Protective effect of masitinib on cardiovascular function of rats with pulmonary hypertension: gender dependence","volume":"38","author":"Kocic","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2019.106599_bb0100","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/2045893217710639","article-title":"Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges","volume":"7","author":"Lajoie","year":"2017","journal-title":"Pulm Circ"},{"key":"10.1016\/j.vph.2019.106599_bb0105","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ejca.2010.02.014","article-title":"Phase II study of oral masitinib mesilate in imatinib-na\u00efve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)","volume":"46","author":"Le Cesne","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.vph.2019.106599_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.vph.2018.07.002","article-title":"Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats","volume":"110","author":"Leong","year":"2018","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2019.106599_bb0115","doi-asserted-by":"crossref","first-page":"509","DOI":"10.56808\/2985-1130.2939","article-title":"Long-term effect of low-dose imatinib therapy for pulmonary hypertension due to chronic degenerative mitral valve disease in six dogs","volume":"48","author":"Leong","year":"2018","journal-title":"Thai J. Vet. Med."},{"key":"10.1016\/j.vph.2019.106599_bb0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.vph.2017.10.006","article-title":"Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats","volume":"100","author":"Leong","year":"2018","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2019.106599_bb0125","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2019.106599_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12931-017-0514-0","article-title":"Imatinib relaxes the pulmonary venous bed of guinea pigs","volume":"18","author":"Maih\u00f6fer","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.vph.2019.106599_bb0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.critrevonc.2013.12.011","article-title":"Masitinib (AB1010), from canine tumor model to human clinical development: where we are?","volume":"91","author":"Marech","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.vph.2019.106599_bb0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","article-title":"Targeted therapies in pulmonary arterial hypertension","volume":"141","author":"Montani","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.vph.2019.106599_bb0145","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2017.08.526","article-title":"Masitinib as an add-on therapy to riluzole is safe and effective in the treatment of amyotrophic lateral sclerosis (ALS)","volume":"381","author":"Mora","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.vph.2019.106599_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.vph.2019.106599_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2011.06.033","article-title":"Imatinib mesylate (Gleevec) as protein-tyrosine kinase inhibitor elicits smooth muscle relaxation in isolated human prostatic tissue","volume":"78","author":"Ozgur-Akdemir","year":"2011","journal-title":"Urology."},{"key":"10.1016\/j.vph.2019.106599_bb0160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1254\/jphs.09110FP","article-title":"Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats","volume":"111","author":"Sawamura","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.vph.2019.106599_bb0165","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00109-013-0998-0","article-title":"Vascular remodeling in pulmonary hypertension","volume":"91","author":"Shimoda","year":"2013","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.vph.2019.106599_bb0170","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.ejca.2009.05.010","article-title":"Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and\/or metastatic solid cancers","volume":"45","author":"Soria","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.vph.2019.106599_bb0175","first-page":"2493","article-title":"Stage-dependent changes of \u03b22-adrenergic receptor signaling in right ventricular remodeling in monocrotaline-induced pulmonary arterial hypertension","volume":"41","author":"Sun","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.vph.2019.106599_bb0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2377-12-36","article-title":"Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study","volume":"12","author":"Vermersch","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.vph.2019.106599_bb0185","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/CIRCRESAHA.109.197533","article-title":"Inhibition of the SDF-1\/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension","volume":"104","author":"Young","year":"2009","journal-title":"Circ. Res."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189119301193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189119301193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:19:06Z","timestamp":1761527946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189119301193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":37,"alternative-id":["S1537189119301193"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2019.106599","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2019.106599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106599"}}